GlobeNewswire by notified

Managers’ transactions


May 25,2023 

Announcement no. 32 

Managers’ transactions 

Pharma Equity Group A/S has today received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in Pharma Equity Group A/S made by persons discharging managerial responsibilities in Pharma Equity Group and/or persons closely related with them.   

1. Details of the person discharging managerial responsibilities/person closely associated

a) Name  

Thomas Kaas Selsø 

2. Reason for the notification 

 a) Position/status  


b) Initial notification/amendment  

Initial notification  

3. Details of the issuer 

a) Name  

Pharma Equity Group A/S  

b) LEI  


c) Trade name 


4. Details of the transaction(s) 

a) Description of the financial instrument, type    of instrument and Identification code  

Shares, ISIN code DK0061155009 

b) Nature of the transaction  


c) Price(s) and volume(s)  

Price: DKK 167,225

Volume: 551,724  

d) Aggregated information  
- Aggregated volume  
- Aggregated price  


e) Date of the transaction  

25-05-2023, 09:26 CEST 

 f) Place of the transaction  

Nasdaq Copenhagen A/S 

For further information, please contact:

Thomas Kaas Selsø, CEO of Pharma Equity Group A/S, phone: 40 22 21 14 

Peter M. Eriksen, Chair of the Board of Directors of Pharma Equity Group A/S, phone: 51 99 66 00. 

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

WithSecure Corporation: Notice pursuant to the Finnish Securities Market Act, Chapter 9, Section 106.6.2023 08:30:00 CEST | Press release

WithSecure Corporation, Stock Exchange Release, 6 June 2023, at 9.30 EEST WithSecure Corporation: Notice pursuant to the Finnish Securities Market Act, Chapter 9, Section 10 WithSecure Corporation has received an announcement from Nordea Funds Ltd. on 2 June 2023, in accordance with the Finnish Securities Market Act Chapter 9, Section 5. According to the announcement, the total number of votes held by Nordea Funds Ltd. decreased to below ten (10) per cent of the total number of votes of WithSecure Corporation on 1 June 2023. Total position of Nordea Funds Ltd. subject to the notification: % of shares and voting rights % of shares and voting rights through financial instruments % of totalTotal number of shares and voting rights of issuer Resulting situation on the date on which threshold was crossed or reached Shares: 9.59% Votes: 9.90% Shares: 9.59% Votes: 9.90% 176,098,739.00 Position of previous notification (if applicable) Shares: 9.81% Votes: 10.12% Shares: 9.81% Votes: 10.12% Noti

Equinor ASA: Share buy-back6.6.2023 08:00:00 CEST | Press release

Please see below information about transactions made under the share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR). Date on which the second tranche of the share buy-back programme for 2023 was announced: 4 May 2023. The duration of the second tranche of the buy-back programme for 2023: 11 May to no later than 25 July 2023. Size of the buy-back programme: Up to 94,000,000 shares, with a maximum total consideration for the second tranche: USD 550,000,000. From 29 May to 2 June, Equinor ASA has purchased a total of 2,117,395 own shares at the Oslo Stock Exchange at an average price of NOK 288.2593 per share. Aggregated overview of transactions per day: DateAggregated volume (number of shares)Weighted average share price (NOK)Total transaction value (NOK)29 May30 May510,000292.4021149,125,071.0031 May560,000284.7080159,436,480.001 June550,000284.5167156,484,185.002 June497,395292.1483145,313,103.68Previously disclosed buy-backs under the second tranche of the 2023 programme 4,0

Progress on share buyback programme6.6.2023 08:00:00 CEST | Press release

Progress on share buyback programme ING announced today that, in line with the launch of our €1.5 billion share buyback programme announced on 11 May 2023, we repurchased 1,711,037 shares during the week of 29 May 2023 up to and including 2 June 2023. The shares were repurchased at an average price of €11.81 for a total amount of €20,199,121.24. For detailed information on the daily repurchased shares, individual share purchase transactions and weekly reports, see the ING website at The total number of shares repurchased under this programme to date is 5,466,433 ordinary shares at an average price of €11.91 for a total consideration of €65,084,362.50. To date approximately 4.34% of the maximum total value of the share buyback programme has been completed. Note for editors For further information on ING, please visit Frequent news updates can be found in the Newsroom or via the @ING_news Twitter feed. Photos of ING operations, buildings and it

Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference6.6.2023 08:00:00 CEST | Press release

Media Release COPENHAGEN, Denmark; June 6, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA, 11:20 AM PDT on June 13, 2023 (2:20 PM EDT / 8:20 PM CEST). A webcast of the fireside chat will be available on Genmab’s website at About Genmab Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function

Sampo plc’s share buybacks 05/06/20236.6.2023 07:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 06/06/2023 at 08:30 am Sampo plc’s share buybacks 05/06/2023 On 05/06/2023 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)7,94943.63AQEU31,84643.50CEUX13,65043.61TQEX66,55543.52XHELTOTAL120,00043.53 *rounded to two decimals On 29 March 2023, Sampo announced a share buyback programme of up to a maximum of EUR 400 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 3 April 2023, is based on the authorisation granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 4,530,623 Sampo A shares representing 0.89 per cent of the total number of shares in Sampo plc. Details o